URMC-099

CHF 120.00
In stock
SYN-1211-M0011 mgCHF 120.00
SYN-1211-M0055 mgCHF 215.00
SYN-1211-M01010 mgCHF 335.00
SYN-1211-M05050 mgCHF 1'137.00
SYN-1211-M100100 mgCHF 1'975.00
 
More Information
Product Details
Synonyms 3-(1H-Indol-5-yl)-5-(4-(4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrrolo[2,3- b]pyridine
Product Type Chemical
Properties
Formula C27H27N5
MW 421.5
CAS 1229582-33-5
Purity Chemicals ≥95% (HPLC)
Appearance Solid.
Solubility Soluble in DMSO or water.
Declaration Manufactured by SYNkinase.
Other Product Data Target: MLK-3 | Kinase Group: TKL

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key QKKIWEILHCXECO-UHFFFAOYSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 3 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Inhibition of mixed lineage kinase 3 (MLK-3) is a potential strategy for the treatment of Parkinson's disease and HIV-1 associated neuro-cognitive disorders (HAND), requiring an inhibitor that can achieve significant brain concentration levels. URMC-099 is an orally bioavailable MLK-3 inhibitor with excellent brain exposure in mouse PK models and minimal interference with key human CYP450 enzymes or hERG channels. URMC-099 inhibits multiple kinase pathways, including MLK-3 (14nM) and leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2) (11nM).
Product References
  1. The new small-molecule mixed-lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of human immunodeficiency virus-associated neurocognitive disorders: D.F. Marker, et al.; J. Neurosci. 33, 9998 (2013)
  2. Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3: V.S. Goodfellow, et al.; J. Med. Chem. 56, 8032 (2013)
  3. MLK3 regulates fMLP-stimulated neutrophil motility: O. Polesskaya, et al.; Mol. Immunol. 58, 214 (2014)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.